Subject characteristics
| Total study subjects | 17 | ||
| Age, median (Range), years | 63 | 48–81 | |
| Sex | Male | 14 | 82 % |
| Female | 3 | 18 % | |
| ECOG PS pretreatment | 0 | 8 | 47 % |
| 1 | 9 | 53 % | |
| Melanoma Sub-Type | Cutaneous | 15 | 88 % |
| Mucosal | 2 | 3 % | |
| Prior lines of therapy, n (%) | 0 | 3 | 18 % |
| 1 | 4 | 24 % | |
| 2 | 4 | 24 % | |
| ≥3 | 6 | 35 % | |
| Median prior lines of therapy (% pretreated) | 2 | 83 % | |
| Prior Interleukin-2 | 5 | 29 % | |
| Prior Ipilimumab | 4 | 24 % | |
| Number of metastatic sites | 1 | 6 | 35 % |
| 2 | 4 | 24 % | |
| ≥3 | 7 | 41 % | |
| M1a | 1 | 6 % | |
| M1b | 5 | 29 % | |
| M1c | 11 | 65 % |